Genmab — Januar 2021
-
-
Asien: Fremgang over hele linjen - kun Japan halter efter.
https://www.proinvestor.com/investornyt/670779/asien-fremgang-over-hele-linjen-kun-japan-halter-efter -
Myeloma patients should be outraged today. @bmsnews raised price of Revlimid & Pomalyst by 4.5%-almost 4x inflation. For pharma apologists who say list doesn't matter-67% of Americans pay some or all of their cost based on list. My oop will jump from $996 to $1,041 every 28 days!
-
Mornings og godt nytår alle! Ser frem til endnu et år med alle jeres guld-kommentarer!

-
Markedet handler 6-8 måneder frem, og ser her et fokus på cykliske-, teknologiske- råvarer- og finansaktier med afsæt i et ophør af Coranasituationen. GEN er en langsigtet aktie, men steg jo 66% i 2020. Lige nu falder dollarkursen og defensive aktier. Sundhedsvæsnet er presset mange steder. Påvirker GEN, men jeg har de lange briller på. Day- og Swingtrader har gode tider:) Er tungt lastet i GEN.
-
@pensionisten Hvordan går det med Genmab-bulls?

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind